Corbus Pharmaceuticals Holdings Inc., of Norwood, Mass., opened enrollment in its phase II study of Resunab for the treatment of skin-predominant dermatomyositis, a rare, inflammatory muscle disease that is accompanied by skin rashes and affects up to about 25,000 individuals in the U.S.